ClinicalTrials.gg
RecruitingNCT06149481Updated Nov 20, 2026

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

A Phase 1/2 interventional study of Retifanlimab and Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform in Metastatic Colorectal Cancer, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.
Updated Nov 20, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Colorectal Neoplasms by National Cancer Institute (NCI) — 19 open to participants now, 35 under way, 1 of them phase 3. Colorectal Neoplasms · National Cancer Institute (NCI).

Planned enrollment
20th of 74
60 · median 37
Started
2024
with 2 others
Phase 1/2
10 of 94
2 open now
Primary completion
2027-10
later than 19 of 33 live
Registered
80th of 94
by date

Among the 94 studies in Colorectal Neoplasms by National Cancer Institute (NCI), this one is the 20th largest by planned enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 1/2, reaches primary completion later than 19 of the 33 other live ones, and was the 80th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

19 of the 94 studies in Colorectal Neoplasms by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Colorectal Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Each year, more than 32,000 people in the United States are diagnosed with colorectal cancer that has returned or progressed after treatment and spread to other organs. This is called metastatic colorectal cancer (mCRC). Most people with mCRC survive only about 2 years.

Objective:

To test the ability of a combination of up to 4 experimental anti-cancer drugs treat mCRC. The names of these drugs are retifanlimab, TriAdeno vaccine, N-803, and SX-682. They are described below.

Eligibility:

Adults aged 18 years or older with mCRC. Participants must have

Design:

Participants will be screened. This includes having a physical exam, blood tests, urine tests, and imaging tests. If signed on to the study, participants will have 2 tumor biopsies. One when starting the study and once about 8 weeks after bring on the study. Participants will receive $500 for each biopsy.

Participants will be treated with either 3 or 4 drugs and will receive a detailed calendar explaining when each drug is given.

Retifanlimab is given every 4 weeks through an IV (an IV is tube attached to a needle inserted into a vein in the arm). N-803 is injected under the skin on the abdomen every 4 weeks.

TriAdeno vaccine is injected under the skin of the upper arm or thigh once a month for 3 doses and then once every 3 months.

Some participants will also receive a 4th drug. SX-682 is a pill taken by mouth. Participants will take this drug 2 times a day at home for about 3 weeks of each month.

Study treatment will continue up to 2 years. Follow-up phone calls/emails may continue for 3 more years.

Read the detailed description

Background:

  • mCRC is incurable and available standard therapies offer a median overall survival of approximately 2 years.
  • Most cases (approximately 95%) of mCRC have an intact expression of DNA mismatch repair enzymes (MLH1, MSH2, MSH6, and PMS2), and are commonly classified as having mismatch repair proficient (pMMR) or microsatellite stable (MSS) mCRC.
  • MSS mCRC does not respond to immune checkpoint inhibitor (ICI) therapy whereas mismatch repair deficient (or microsatellite instability-high) mCRC is responsive to ICI therapy.
  • Preclinical and clinical studies conducted at the NCI in the Laboratory of Tumor Immunology Biology (LTIB) indicate that the combination of programmed cell death protein 1 (PD-1) / Programmed death-ligand 1 (PD-L1) blockade, tumor-associated antigens (TAA) targeted vaccine, IL15 agonist, and CXCR1/2 inhibition may include sufficient immune enhancements to produce anti-tumor activity in MSS mCRC.
  • Retifanlimab is a humanized IgG4 monoclonal antibody that targets PD-1. Retifanlimab has been studied in several clinical trials, and several malignancies, and has a safety and clinical activity profile similar to approved anti-PD-1 therapies (e.g., pembrolizumab).
  • The TriAdeno Vaccine employs 3 adenovirus serotype 5 vectors, encoding three TAAs (CEA, MUC1, and brachyury). These vaccines have completed the phase 1 study and are safe and well tolerated. Vaccination generates antigen-specific T cell responses to CEA, MUC1, and brachyury.
  • N-803 is an IL-15 agonist that activates and expands T cells and NK cells. N-803 enhances anti-tumor activity in combination with tumor-targeted vaccines. Clinically, multiple studies have demonstrated the safety of tumor-targeted vaccine in combination with PD- 1/PD-L1 blockade. Adding N-803 to PD-1/PD-L1 blockade can produce antitumor responses in disease states where responses to PD-1/PD-L1 alone would not be expected.
  • SX-682 is a small molecule, orally bioavailable, allosteric antagonist of the chemokine receptors CXCR1 and CXCR2. Inhibition of CXCR1 and CXCR2 addresses a major component of intratumoral T cell suppression by myeloid-derived suppressor cells and tumor-associate macrophages. SX-682 has shown to be tolerable in combination with PD- 1/PD-L1 blockade.

Objectives:

  • Phase I: to describe the safety profile of the Immuno-Oncology (IO) regimens consisting of retifanlimab, TriAdeno vaccine, N-803 (A1), and retifanlimab, TriAdeno vaccine, N- 803, SX 682 (A2) in participants with metastatic colorectal cancer (mCRC).
  • Phase II: to determine the objective response rate (ORR) (complete response (CR) + partial response (PR)) of the IO regimen in mCRC.

Eligibility:

  • Age >=18 years.
  • Previously treated metastatic colorectal cancer with measurable disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status \<= 2.
  • Adequate organ function.

Design:

  • This is an open-label Phase I/II trial to evaluate the safety and efficacy of the Immuno- Oncology regimen, consisting of retifanlimab, TriAdeno vaccine, N-803, and SX-682 in participants with mCRC.
  • During Phase I, we will assess the safety of the three- and the four-drug IO regimens.
  • Phase II uses a Simon optimal two-stage design at SX-682 200 mg BID. Enrollment at 200 mg BID begins with a safety lead-in of 5 to 6 DLT-evaluable participants. Provided the predefined safety criteria are met (0 DLTs among the first 5 participants or \<=1 DLT among the first 6), accrual will continue without interruption until a total of 9 responseevaluable participants have been treated with the four drug regimen with SX-682 at 200 mg BID. Participants enrolled during the safety lead-in who are response-evaluable will count toward the Stage 1 total of 9.
  • If 0 to 1 confirmed responses (CR+PR by RECIST v1.1 within 24 weeks) are observed among these 9 participants, accrual will stop for futility. If >=2 responses are observed, enrollment will expand to a total of 23 response-evaluable participants at 200 mg BID.
  • Participants will receive treatment in cycles consisting of 28 (+7) days for 2 years.
  • To allow for a small number of inevaluable participants, and screen failures the accrual ceiling will be set at 60.
03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Monoclonal Antibody
  • Brachyury
  • MUC-1
  • Immunoglobulin G cytokine fusion protein
  • chemokine antagonist
  • Small Molecule
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed colorectal cancer and evidence of disease.
  • Participants must have received, been ineligible to receive, or refused to receive two lines of standard systemic therapy i.e., a fluoropyrimidine with oxaliplatin or irinotecan with bevacizumab, regorafenib, trifluridine, and (if history of RAS wild-type) EGFR-targeted therapy. Participants must have received one line of systemic if history of advanced microsatellite instability-high [MSI-H/dMMR]) metastatic colon cancer.
  • Participants who had progressive disease within 6 months before study treatment following standard therapy are eligible if they have not received systemic therapy for metastatic disease. Participants with a history of MSI-H/dMMR must have also received one line of checkpoint inhibitor therapy.
  • Age >= 18 years.
  • per 1.1.
  • performance status \<= 2.
  • Adequate organ and marrow as a function defined below:

    • (ANC) >= 1,500 cells/mm\^3
    • count >= 100,000 cells/mm\^3
    • (Hgb) >= 9 g/dL
    • total level \<= 1.5 x (ULN)ULN; except participants with Gilbert's syndrome, who may be enrolled if the conjugated bilirubin is within normal limits or total bilirubin is \<= 3 x ULN. Participants with liver metastases and a total bilirubin >1.5 x ULN but \<= 2.0 x ULN may be enrolled at the discretion of the Investigator in consultation with the Sponsor.
    • (ALT) \<= 2.5 x ULN OR \<= 5 x ULN for participants with liver metastases
    • aspartate aminotransferase (AST) level \<= 2.5 x ULN OR \<= 5 x ULN for participants with liver metastases
    • (CrCl) calculated by Cockroft-Gault formula >= 50 mL/min
  • Resolution of toxic effect(s) of prior anti-cancer therapy (except alopecia and neuropathy) to Grade \<=1 or to \<=2 if effective medical management of those toxicities is in place such that they are controlled per standard of care (e.g., grade 2 hypothyroidism requiring oral thyroid replacement).
  • Participants with treated are eligible if clinically appropriate follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
  • Participants positive for (HIV) are eligible if they are compliant with appropriate anti-retroviral therapy for at least 6 months, have HIV viral load \<400 copies/mL, and a > 350 cells/microliter at screening.
  • Participants positive for virus (HCV) are eligible if they have completed definitive anti-viral therapy and have an undetectable viral load.
  • Individuals of (IOCBP) and individuals who can father children must agree to use an effective method of (barrier, hormonal, intrauterine device [IUD], surgical sterilization) at study entry and up to 6 months after the last dose of the study drug(s).
  • Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 6 months after study treatment discontinuation.
  • Participants must have lesion(s) accessible for (other than used for measurement of disease) and be willing to undergo mandatory study biopsies in the phase 1 portion of the study. Lesions to be biopsied will be determined safely accessible by the provider performing the biopsy (e.g. interventional radiology if a liver or lung biopsy) prior to performing the biopsy. Note: If Phase 2 opens, per the investigator s discretion, if biopsy is strenuous to obtain, e.g., no easily accessible lesions are available or the subject

condition is not amenable for biopsy, then the subject will be eligible for enrollment without biopsy at screening and for continuation of treatment without on-treatment study biopsy.

-Participants must be able to understand and willing to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

  • Participants with prior drug, chemotherapy, immunotherapy, or any prior therapeutic radiotherapy within 14 days prior to study treatment initiation.
  • Participants with palliative radiotherapy performed within 7 days prior to study treatment initiation.
  • Active disease requiring systemic in excess of physiologic maintenance doses of (> 10 mg/day of prednisone or equivalent) with the exception of:

    • intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections in participants with asthma
    • using topical, ocular, intra-articular, or intranasal corticosteroids (with minimal systemic absorption
    • brief courses of corticosteroids for prophylaxis (e.g., contrast dye allergy).
  • Evidence of interstitial lung disease, history of interstitial lung disease, or active, noninfectious pneumonitis. Participants with chronic post-radiation pulmonary changes/scarring that is asymptomatic are eligible.
  • Active infections requiring systemic antibiotics or antifungal or antiviral treatment within 8 days prior to treatment initiation. Participants who have had appropriate antibiotics initiated but are still completing the treatment course are eligible if clinically improved or had minimal symptoms at presentation (e.g., urinary tract infection or pharyngeal streptococcal infection without evidence of systemic inflammatory response).

    • History of organ transplant, including stem cell transplantation.
    • Participants who experienced immune-related toxicity during prior therapy for which permanent discontinuation of therapy was recommended (per product label or consensus guidelines) or any immune-related toxicity requiring active (current) systemic corticosteroids (with the exception of endocrinopathy that is well controlled on replacement hormones).
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drugs.
  • Receipt of a within 28 days prior to treatment initiation. Note: Examples of live vaccines include but are not limited to measles, mumps, rubella, varicella-zoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza vaccines for injection are generally killed-virus vaccines and are allowed; however, intranasal influenza vaccines are live, attenuated vaccines and are not allowed.
  • History of infection with virus (HBV) unless on suppressive therapy. Individuals with serologic evidence of a resolved prior HBV infection (i.e., HBsAgnegative and anti-HBc positive) are eligible.
  • Pregnancy confirmed with Beta-human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test performed in IOCBP at screening.
  • Uncontrolled intercurrent illness that would limit compliance with study requirements.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Retifanlimab + TriAdeno Vaccine + N-803

    Drug: Retifanlimab · Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform · Drug: N-803

  • Experimental
    Arm 2

    Retifanlimab + TriAdeno Vaccine + N-803 + SX-682

    Drug: Retifanlimab · Biological: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform · Drug: N-803 · Drug: SX-682

Interventions

  • 500 mg infused via IV over 30 minutes every 28 days

  • BiologicalTherapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform

    5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh on Day 1 of Cycles 1, 2, 3 and every 3 cycles after that

  • DrugNogapendekin alfa inbakiceptStudies of Nogapendekin alfa inbakiceptNogapendekin alfa inbakicept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    15 ug/kg administered via subcutaneous injection to the abdomen every 28 days

  • DrugSX-682

    200 mg administered orally twice per day on days 6-26 of every cycle

06

What researchers measure

Primary outcomes

  1. Phase I: Safety profiles of the IO regimens consisting of retifanlimab, TriAdeno vaccine, N-803 (A1), and retifanlimab, TriAdeno vaccine, N-803, SX-682 (A2) in participants with metastatic colorectal cancer

    Number of DLTs within DLT period (C1 days 1-28). Any toxicities identified.

    Time frame: Day 1 of Cycle 1 through 30 days after the last study drug administration

  2. Phase II: Overall response rate (ORR) defined as the CR+PR of the IO regimen in mCRC

    The fraction of participants with a CR or PR (per RECIST v1.1) in Phase II will be reported along with a 95% confidence interval.

    Time frame: Every 8 weeks until either disease progression or 2 years after initiation of study therapy.

Secondary outcomes

  1. Progression Free Survival (PFS) at 6, 12, and 24 months

    PFS will be determined by the Kaplan-Meier method and reported at 6, 12, and 24 months from the date the participant was enrolled in the trial, along with 95 percent confidence intervals at these times.

    Time frame: Every 8 weeks until disease progression or for 2 years after initiation of study therapy

  2. Disease control rate (DCR) at 6 and 12 months

    DCR at 6 and 12 months will be reported as a fraction along with a 95 percent confidence interval for each.

    Time frame: Every 8 weeks until disease progression or 1 year after initiation of study therapy

  3. Safety during Phase II

    AEs will be reported by type and grade within Phase II.

    Time frame: From Day 1 to 30 days of the last study drug administration

  4. Overall survival

    Monitoring of participants from Day 1 of each cycle, at follow up visits and until date of death/closure of the study.

    Time frame: Up to 2 years after start of study therapy

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • NCIMO Referral · ContactNCIMO_Referrals@mail.nih.gov · Not Listed
    • National Cancer Institute Referral Office · Contact(888) 624-1937
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD will be shared. All IPD recorded in the medical record will be shared with intramural investigators upon request. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data from this study may be requested from other researchers within 10 years after the completion of the primary endpoint. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

Access criteria: Data from this study may be requested by contacting the PI. Genomic data are made available via dbGaP through requests to the data custodians.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2027, 43 months after the start.

Of 102 non-industry phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 43 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2023
First posted
Nov 29, 2023
StartActual
Mar 26, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore total bilirubin level < 1.5 x upper limit of normal (ULN)Now total bilirubin level <= 1.5 x upper limit of normal (ULN)ULN; except participants with Gilbert's syndrome, who may be enrolled if the conjugated bilirubin is within normal limits or total bilirubin is <= 3 x ULN. Participants with liver metastases and a total bilirubin >1.5 x ULN but <= 2.0 x ULN may be enrolled at the discretion of the Investigator in consultation with the Sponsor.
Exclusion criteria
  • EditedParticipants who experienced immune-related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy was recommended (per product label or consensus guidelines) or any immune-related toxicity requiring active (current) systemic corticosteroids (with the exception of endocrinopathy that is well controlled on replacement hormones).
Nov 20, 2026
Show all 4 updates
  1. Nov 20, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore total bilirubin level < 1.5 x upper limit of normal (ULN)Now total bilirubin level <= 1.5 x upper limit of normal (ULN)ULN; except participants with Gilbert's syndrome, who may be enrolled if the conjugated bilirubin is within normal limits or total bilirubin is <= 3 x ULN. Participants with liver metastases and a total bilirubin >1.5 x ULN but <= 2.0 x ULN may be enrolled at the discretion of the Investigator in consultation with the Sponsor.
    Exclusion criteria
    • EditedParticipants who experienced immune-related toxicity during prior checkpoint inhibitor therapy for which permanent discontinuation of therapy was recommended (per product label or consensus guidelines) or any immune-related toxicity requiring active (current) systemic corticosteroids (with the exception of endocrinopathy that is well controlled on replacement hormones).
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 16, 2026
    Minor edits only
    + 1 other change: verification date
  4. Sep 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06149481
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Mar 26, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

NCI Referral Office
Contact
ncimo_referrals@nih.gov
(888) 624-1937
Nicholas P Tschernia, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Retifanlimab · Nogapendekin alfa inbakicept

Start the discussion